Heart and Vessels

, Volume 34, Issue 10, pp 1595–1599 | Cite as

Prevalence of Achilles tendon xanthoma and familial hypercholesterolemia in patients with coronary artery disease undergoing percutaneous coronary intervention

  • Hideki KitaharaEmail author
  • Naoto Mori
  • Yuichi Saito
  • Takashi Nakayama
  • Yoshihide Fujimoto
  • Yoshio Kobayashi
Original Article


Familial hypercholesterolemia (FH) is reportedly associated with the development of coronary artery disease (CAD), especially acute coronary syndrome (ACS). However, the prevalence of FH in patients with stable CAD is still unclear. The aim of this study was to investigate the prevalence of Achilles tendon xanthoma (ATX) and heterozygous FH in patients with stable CAD and ACS undergoing percutaneous coronary intervention (PCI). A total of 423 patients with CAD (273 stable CAD and 150 ACS) undergoing PCI at Chiba University Hospital between June 2016 and February 2018 were enrolled in this study. Soft X-ray radiography of the Achilles tendon was performed in all patients, and a maximum thickness of 9 mm or more is regarded as ATX. Heterozygous FH was diagnosed according to the Japan Atherosclerosis Society Guidelines. In comparisons between stable CAD and ACS patients, ATX was observed in 9.2% vs. 15.3% (p = 0.055), and heterozygous FH was diagnosed in 3.7% vs. 5.3% (p = 0.416), respectively. Among ACS patients, those with ST elevation myocardial infarction (STEMI) showed the highest prevalence of ATX (19.5%) and FH (7.3%). Whereas ATX and heterozygous FH were considerably observed in patients with ACS, a certain number of ATX and heterozygous FH were also detected in stable CAD patients.


Coronary artery disease Familial hypercholesterolemia Achilles tendon xanthoma 



This study was not funded by any organizations or sponsors.

Compliance with ethical standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Boren J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 34:3478–3490aCrossRefGoogle Scholar
  2. 2.
    Mabuchi H, Koizumi J, Shimizu M, Takeda R (1989) Development of coronary heart disease in familial hypercholesterolemia. Circulation 79:225–232CrossRefGoogle Scholar
  3. 3.
    Mundal L, Sarancic M, Ose L, Iversen PO, Borgan JK, Veierod MB, Leren TP, Retterstol K (2014) Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992–2010. J Am Heart Assoc 3:e001236CrossRefGoogle Scholar
  4. 4.
    Krogh HW, Mundal L, Holven KB, Retterstol K (2016) Patients with familial hypercholesterolaemia are characterized by presence of cardiovascular disease at the time of death. Eur Heart J 37:1398–1405CrossRefGoogle Scholar
  5. 5.
    Ohmura H, Fukushima Y, Mizuno A, Niwa K, Kobayashi Y, Ebina T, Kimura K, Ishibashi S, Daida H (2017) Estimated prevalence of heterozygous familial hypercholesterolemia in patients with acute coronary syndrome. Int Heart J 58:88–94CrossRefGoogle Scholar
  6. 6.
    Inohara T, Kohsaka S, Yamaji K, Amano T, Fujii K, Oda H, Uemura S, Kadota K, Miyata H, Nakamura M (2017) Impact of institutional and operator volume on short-term outcomes of percutaneous coronary intervention: a report from the Japanese Nationwide Registry. JACC Cardiovasc Interv 10:918–927CrossRefGoogle Scholar
  7. 7.
    Bujo H, Takahashi K, Saito Y, Maruyama T, Yamashita S, Matsuzawa Y, Ishibashi S, Shionoiri F, Yamada N, Kita T (2004) Clinical features of familial hypercholesterolemia in Japan in a database from 1996–1998 by the research committee of the ministry of health, labour and welfare of Japan. J Atheroscler Thromb 11:146–151CrossRefGoogle Scholar
  8. 8.
    Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S (2018) Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb 25:846–984CrossRefGoogle Scholar
  9. 9.
    Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD (2012) Third universal definition of myocardial infarction. J Am Coll Cardiol 60:1581–1598CrossRefGoogle Scholar
  10. 10.
    De Backer G, Besseling J, Chapman J, Hovingh GK, Kastelein JJ, Kotseva K, Ray K, Reiner Z, Wood D, De Bacquer D (2015) Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 241:169–175CrossRefGoogle Scholar
  11. 11.
    Civeira F (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173:55–68CrossRefGoogle Scholar
  12. 12.
    Scientific Steering Committee on behalf of the Simon Broome Register Group (1991) Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303:893–896CrossRefGoogle Scholar
  13. 13.
    Harada T, Inagaki-Tanimura K, Nagao M, Sato Y, Sudo M, Okajima F, Sugihara H, Oikawa S (2017) Frequency of Achilles Tendon xanthoma in patients with acute coronary syndrome. J Atheroscler Thromb 24:949–953CrossRefGoogle Scholar
  14. 14.
    Rosenson RS (1993) Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933–940CrossRefGoogle Scholar
  15. 15.
    Wattanasuwan N, Khan IA, Gowda RM, Vasavada BC, Sacchi TJ (2001) Effect of acute myocardial infarction on cholesterol ratios. Chest 120:1196–1199CrossRefGoogle Scholar
  16. 16.
    Tanaka S, Ikari Y, Ijichi T, Nakazawa G (2017) Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention. Cardiovasc Interv Ther 32:358–364CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cardiovascular MedicineChiba University Graduate School of MedicineChibaJapan

Personalised recommendations